Southpoint Capital Advisors Cuts Stake in Fennec Pharmaceuticals Amid Challenges

Southpoint Capital Advisors has reduced its stake in Fennec Pharmaceuticals by 27.08%, leaving it with 2.74 million shares. The firm's overall portfolio was impacted by -0.2%. Fennec Pharmaceuticals has a market capitalization of $264.472 million and a GF Value of $11.94, indicating a "Possible Value Trap." The company's financial metrics, including ROA of -14.25% and cash to debt ratio of 1.13, suggest financial challenges.